Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00641_DB08827_nanopub.RA4kNCA8xSuv9LkkX5xmVcxxsq1nXngbXUWR2rVU5lvhk#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00641_DB08827 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00641_DB08827 label "DDI between Simvastatin and Lomitapide - Simvastatin plasma concentrations are doubled by lomitapide. To prevent dose related adverse effects such as myopathy and rhabdomyolysis it is recommended to reduce the dose of simvastatin by 50%. See FDA label for additional dosage instructions. [drugbank_resource:DB00641_DB08827]" assertion.
- drugbank_resource:DB00641_DB08827 identifier "drugbank_resource:DB00641_DB08827" assertion.
- drugbank_resource:DB00641_DB08827 title "DDI between Simvastatin and Lomitapide - Simvastatin plasma concentrations are doubled by lomitapide. To prevent dose related adverse effects such as myopathy and rhabdomyolysis it is recommended to reduce the dose of simvastatin by 50%. See FDA label for additional dosage instructions." assertion.
- drugbank:DB08827 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00641_DB08827 assertion.
- drugbank:DB00641 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00641_DB08827 assertion.